[Skip to Content]
[Skip to Content Landing]
Other Articles
March 2, 1963

Effect of Dextrothyroxine on Metabolism of C14-Labeled Cholesterol and Tripalmitin

Author Affiliations

Philadelphia

From the Radioisotope and Medical Services, Philadelphia Veterans Administration Hospital. Director, Research and Development, Radioisotope Service, Veterans Administration Hospital, and Assistant Professor of Biochemistry, University of Pennsylvania School of Medicine (Dr. Rabinowitz); Chief, Cardiopulmonary Function Laboratory, Veterans Administration Hospital, and Assistant Professor of Medicine, Temple University School of Medicine (Dr. Rodman); and Assistant Chief, Medical Service, Veterans Administration Hospital, and Clinical Professor of Medicine, Woman's Medical College (Dr. Myerson).

JAMA. 1963;183(9):758-760. doi:10.1001/jama.1963.63700090004013a
Abstract

THE POSSIBLE RELATIONSHIP of hypercholesteremia to atherosclerosis had led to consideration of thyroxine as a useful agent in lowering serum cholesterol.1,3 Since the dose of L-thyroxine required for this purpose usually produces hypermetabolic effects,3 many analogues of thyroxine have been tested in an attempt to find one with a predominantly cholesterol-lowering action.4,5 This study was undertaken to determine the effect of oral dextrothyroxine (D-T4) on the metabolism of intravenously administered C14-labeled cholesterol and tripalmitin.

Materials and Methods  Twenty-two euthyroid male patients with high serum cholesterol levels, various arteriosclerotic disorders, or both were studied. No changes were made in any patient's program other than addition of the drug. The biological half-life of C 14-labeled cholesterol and tripalmitin in serum was determined for each patient for 30 days before and after the administration of 8 mg. of D-T4 daily. Respiratory quotient, oxygen uptake,

First Page Preview View Large
First page PDF preview
First page PDF preview
×